Roche says a second trial of Actemra revives hopes for IL-6. What now?
Roche’s Actemra — and the IL-6 drug class by extension — may have a role in the fight against Covid-19 after all.
Data from a new Phase III study showed that adding the drug to standard of care could reduce hospitalized patients’ likelihood of needing mechanism ventilation, the Swiss pharma giant reported. Importantly, the majority of the 389 enrolled patients are from minority racial and ethnic groups who are often underrepresented in clinical trials but bear the brunt of the pandemic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
